- Home
- DAWN vs BDN Comparison
DAWN vs BDN Comparison
Compare DAWN & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- BDN
- Stock Information
- Founded
- DAWN 2018
- BDN 1986
- Country
- DAWN United States
- BDN United States
- Employees
- DAWN N/A
- BDN N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- BDN Real Estate Investment Trusts
- Sector
- DAWN Health Care
- BDN Real Estate
- Exchange
- DAWN Nasdaq
- BDN Nasdaq
- Market Cap
- DAWN 624.8M
- BDN 693.1M
- IPO Year
- DAWN 2021
- BDN N/A
- Fundamental
- Price
- DAWN $7.15
- BDN $4.53
- Analyst Decision
- DAWN Strong Buy
- BDN Hold
- Analyst Count
- DAWN 7
- BDN 1
- Target Price
- DAWN $27.86
- BDN $5.00
- AVG Volume (30 Days)
- DAWN 1.1M
- BDN 2.0M
- Earning Date
- DAWN 10-29-2025
- BDN 10-21-2025
- Dividend Yield
- DAWN N/A
- BDN 13.22%
- EPS Growth
- DAWN N/A
- BDN N/A
- EPS
- DAWN N/A
- BDN N/A
- Revenue
- DAWN $187,638,000.00
- BDN $306,596,000.00
- Revenue This Year
- DAWN $12.56
- BDN $55.21
- Revenue Next Year
- DAWN $48.02
- BDN $3.34
- P/E Ratio
- DAWN N/A
- BDN N/A
- Revenue Growth
- DAWN 2190.50
- BDN N/A
- 52 Week Low
- DAWN $5.64
- BDN $3.41
- 52 Week High
- DAWN $16.76
- BDN $6.54
- Technical
- Relative Strength Index (RSI)
- DAWN 51.15
- BDN 66.74
- Support Level
- DAWN $7.03
- BDN $4.26
- Resistance Level
- DAWN $7.58
- BDN $4.46
- Average True Range (ATR)
- DAWN 0.27
- BDN 0.11
- MACD
- DAWN -0.04
- BDN 0.03
- Stochastic Oscillator
- DAWN 29.55
- BDN 94.51
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.